blank
blank

PPI in the Joint Funding Scheme

1:1

PPI is integrated throughout the Joint Funding Scheme. There are specific questions set out in the application form on PPI. In addition, at the Review Panel meeting, PPI is reviewed in the applications and a PPI rating contributes to the consensus panel score. It is therefore important to think about PPI from the very start of planning a research project and submitting an application to the Joint Funding Scheme.

HRCI has produced three case studies of PPI excellence in Joint Funding Scheme applications. The case studies outline the PPI plans and activities the applicants had laid out.  You can read them below and we thank the applicants and the HRCI members that they submitted their proposals to, for allowing us to share their excellent plans.

Acces this publication
Captura de pantalla 2026-05-14 093355

Year of publication

2026

Author

HRCI

You might also be interested in

2

ERDERA launches Clinical Trial Call 2026 to advance early‑phase clinical trials for rare diseases

ERDERA (the European Rare Diseases Research Alliance) has opened its Clinical Trial Call to support multinational early-phase clinical trials in rare diseases. The call will fund studies designed to generate robust clinical evidence, strengthen regulatory readiness and make rare disease trials more feasible across countries.
ECRD 2026

ECRD 2026 in Prague strengthens the push for a coordinated EU Action Plan on rare diseases

On 3–4 June, EURORDIS–Rare Diseases Europe and Orphanet convened the rare disease community at ECRD 2026 in Prague around a shared call for coordinated European action, including the forthcoming European Blueprint for Rare Diseases.
ERDERA Open Academy 2026

Open Academy x ERDERA Schools in Barcelona strengthen practical links between patient advocacy and rare disease research

The 2026 Open Academy x ERDERA Schools in Barcelona brought patient advocates and early-career researchers together for practical training on medicines development, translational research and meaningful participation in rare disease research.
Sveriges riksdag (house of parlament).

Sweden adopts first national strategy for rare health conditions

Sweden has adopted its first national strategy for rare health conditions, aiming to improve coordination, equity and access to care between 2026 and 2030.

ERDERA's

search form